9 Biggest Mid-Day Gainers For Monday

shares jumped 105.5 percent to $2.12 amid news of merger with Zone Technologies.

shares rose 81.11 percent to $7.19 in pre-market trading after the company reported data that showed significant overall survivor benefit in rGBM patients receiving VB-111 versus historical Avastin.

shares climbed 65.15 percent to $7.27 after the company issued updated data from its DNA damage response program on seliciclib and sapacitabine combo in patients with solid tumors.

shares jumped 48.55 percent to $3.58 after the company reported that it was awarded a 10-year Indefinite Quantity Airport Security Screening Services contract with the DHS Transportation Security Administration.

shares surged 23.37 percent to 4.54 after the company reported preliminary financial results for the first quarter. The company projects to report profit in the quarter.

rose 19.33 percent to $1.42.

agreed to acquire Dutch business of Ciber for $25 million in cash.

rose 10.70 percent to $7.30 in pre-market trading. Exelixis and its partner

reported positive positive overall survival results from subgroup analyses of Phase 3 trial of CABOMETYX tablets in advanced renal cell carcinoma.

rose 9.49 percent to $4.15 in pre-market trading after the company reported positive Phase 3 Beacon CRC trial results.

shares gained 7.97 percent to $60.70 as the company reported stronger-than-expected earnings for its second quarter.